Poor right ventricular function is associated with impaired exercise capacity and ventilatory efficiency in transthyretin cardiac amyloid patients
- 12 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Internal and Emergency Medicine
- Vol. 16 (3), 653-660
- https://doi.org/10.1007/s11739-020-02474-1
Abstract
CardioPulmonary Exercise Test (CPET) is the gold standard to evaluate functional capacity in patients at high risk of heart failure (HF). Few studies with a limited number of subjects and conflicting results, analyzed the role of CPET in patients with systemic amyloidosis. Aims of our study were the assessment of the response to exercise in patients with Transthyretin amyloid (ATTR) cardiomyopathy (CA), and the correlation of clinical, biohumoral and echocardiographic parameters with CPET parameters, such as VO2 peak and VE/VCO2 slope. From February 2018 to March 2019, 72 cardiac ATTR patients were prospectively enrolled and underwent a complete clinical, biohumoral, echocardiographic and CPET assessment. All patients completed the exercise stress test protocol, without any adverse event. At CPET, they achieved a mean VO2 peak of 14 mL/Kg/min and a mean VE/VCO2 slope of 31. The blood pressure response to exercise was inadequate in 26 (36%) patients (flat in 25 and hypotensive in 1), while 49/72 patients (69%) showed an inadequate heart rate recovery. In multivariate analysis, s’ tricuspidalic was the only independent predictor of VO2 peak, while in the two test models performed to avoid collinearity, both TAPSE and s’ tricuspidalic were the strongest independent predictors of VE/VCO2 slope. Our data demonstrate the role of right ventricular function as an independent predictor of exercise capacity and ventilatory efficiency in ATTR. In CPET evaluation, a significant proportion of patients presented an abnormal arterial pressure response and heart rate variation to exercise.Keywords
This publication has 39 references indexed in Scilit:
- Prolonged Mean Vo 2 Response Time in Systolic Heart FailureCirculation: Heart Failure, 2013
- Validation of a Cardiopulmonary Exercise Test Score in Heart FailureCirculation: Heart Failure, 2013
- Clinical Recommendations for Cardiopulmonary Exercise Testing Data Assessment in Specific Patient PopulationsCirculation, 2012
- Anxiety and depression among AL amyloidosis patients: the role of cardiac symptomsAmyloid, 2012
- Right ventricular function in AL amyloidosis: characteristics and prognostic implicationEuropean Heart Journal – Cardiovascular Imaging, 2011
- Asymptomatic homozygous gene carrier in a family with Ile68Leu ATTR amyloidosis: a new endemic region in northern Tuscany?Journal of Cardiovascular Medicine, 2011
- Clinician’s Guide to Cardiopulmonary Exercise Testing in AdultsCirculation, 2010
- Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99mTc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid ScintigraphyJournal of the American College of Cardiology, 2005
- Validation of peak exercise oxygen consumption and the Heart Failure Survival Score for serial risk stratification in advanced heart failureThe American Journal of Cardiology, 2005
- Molecular Mechanisms of AmyloidosisThe New England Journal of Medicine, 2003